Poster Session B
Saturday, Sept. 29, 2018
1–3:30 p.m.

B01 Exploring RasGRP1 as a Biomarker for Colorectal Cancer. Oghenekevwe Gbenedio, University of California, San Francisco, San Francisco, CA, USA.

B02 Emerging role for membrane therapy in shaping aberrant Wnt signaling. Alfredo Erazo-Oliveras, Texas A&M University, College Station, TX, USA.

B03 Wnt regulation of mRNA splicing in colon crypts and colon cancer. Amber Habowski, University of California Irvine, Irvine, CA, USA.

B04 Lef1 is a downstream target of Prox1 that regulates Lgr5+ cancer stem cells and intestinal tumorigenesis. Sarika Heino, Translational Cancer Biology Program, Translational Cancer Biology Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

B05 Elimination of one Apc allele in the stem/progenitor compartment of Lrig1 null mice results in rapid and dramatic upregulation of EGFR and Wnt signaling. Won Jae Huh, Vanderbilt University, Nashville, TN, USA.

B06 The transcription factor HNF4A is a key regulator of the intestinal stem cell niche by regulating the expression of WNT3. Christine Jones, Université de Sherbrooke, Sherbrooke, Qc, Canada.

B07 A tumor suppressive PKC-ERK signaling axis in the intestine/colon. Navneet Kaur, University of Nebraska Medical Center, Omaha, NE, USA.

B08 Regulation of cancer stem cell population by SOX2 through interaction with miR29a and HDAC4 in colorectal cancer. Tae Il Kim, Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.

B09 Elucidating the role of Foxl1+ telocytes in providing non-canonical Wnt signaling to the intestinal epithelium. Ayano Kondo, University of Pennsylvania, Philadelphia, PA, USA.

B10 PKCα engages non-canonical TGF-β signaling to suppress inhibitor of DNA binding 1 (Id1) expression in intestinal epithelial cells. Xinyue Li, Eppley Institute, University of Nebraska Medical Center, Omaha, NE, USA.

B11 GSK3β-mediated phosphorylation of TRAF6 inhibits autophagy-dependent non-classical β-catenin degradation and promotes colorectal cancer metastasis. Jian-Ming Li, Sun Yat-sen Memorial Hospital, Guangzhou, China.
Poster Session B  
Saturday, Sept. 29, 2018  
1–3:30 p.m.

B12 Ral Small GTPase signaling controls stem cell dynamics by promoting internalization of WNT signalosomes. Máté Nászai, University of Glasgow, Glasgow, United Kingdom.

B13; PR02 LGR4 is mechanistically different from LGR5 in potentiating Wnt/β-catenin signaling. Soohyun Park, University of Texas Health Science Center at Houston, Houston, TX.

B14 SHP-2 promotes intestinal epithelial regeneration, tumorigenesis and protects against mucosal erosion. Nathalie Rivard, Université de Sherbrooke, Sherbrooke, Quebec, Canada.

B15 A pathway of fibroblast-stem cell interaction required for the initiation of intestinal tumorigenesis. Manolis Roulis, Yale School of Medicine, New Haven, CT, USA.


B17 Utilizing the Sun1-Gfp nuclear isolation tool for transcriptomic and genomic profiling of Foxl1+ telocytes. Avital Swisa, University of Pennsylvania, Philadelphia, PA, USA.

B18 Defining the Wnt-secreting niche that promotes the renewal of intestinal epithelial stem cells. Tomas Valenta, 1) Institute of Molecular Genetics of the ASCR / 2) Institute of Molecular Life Sciences, University of Zurich, 1) Prague / 2) Zurich, 1) Czech Republic / 2) Switzerland.

B19 Enteric glial cells promote colon cancer stem cell chemoresistance via an ATM-dependent pathway. Laurianne Van Landeghem, Department of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, USA.

B20 CD44 functions in Wnt signaling by regulating LRP6 stability, localization and activation. Romina Walter, Karlsruhe Institute of Technology, Institute of Toxicology and Genetics, Karlsruhe, Germany.

B21 KRAS mutation increases colon cancer stem cell properties through DCLK1’s beta-promoter-driven alternative splice variant. Nathaniel Weygant, University of Oklahoma HSC, Oklahoma City, OK, USA.

B22 Elucidating the role of mRNA-binding protein IMP1 in regulating adherens junction complex proteins in the intestinal epithelium. Priya Chatterji, University of Pennsylvania, Philadelphia, PA, USA.
Poster Session B
Saturday, Sept. 29, 2018
1–3:30 p.m.


B24 The functional role of the miR-17-92 cluster in colorectal adenoma-to-carcinoma progression. Sanne Martens-de Kemp, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

B25 Clinicopathologic characteristics and oncologic outcomes of sporadic early-onset colorectal cancer. Ji Won Park, Seoul National University College of Medicine, Houston, TX, USA.

B26 Personalized medicine has the potential to improve efficacy of CRC containing the Pro47Ser single nucleotide polymorphism of p53. Thibaut Barnoud, The Wistar Institute, Philadelphia, PA, USA.

B27 Drug treated cancer-associated fibroblasts promote resistance to EGFR inhibition in colorectal cancer through increased EGF secretion. Colleen Garvey, Lawrence J. Ellison Institute of Transformative Medicine, University of Southern California, Los Angeles, CA, USA.

B28 Improved efficacy of the novel polymeric fluoropyrimidine F10 to orthotopic xenograft models of colorectal cancer. William Gmeiner, Wake Forest School of Medicine, Winston-Salem, NC, USA.

B29 Co-inhibition of BET proteins and NF-κB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions. Chen-Ying Liu, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

B30 Non-estrogenic derivatives of xanthohumol, dihydroxanthohumol and tetrahydroxanthohumol, inhibit growth and increase apoptosis of colon carcinoma and hepatoma cell lines. Isabelle Logan, Oregon State University, Corvallis, OR, USA.

B31 Transient enhancement of p53 activity mitigates radiation-induced gastrointestinal toxicity. Vinod Pant, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

B32 To explore the effect of novel β-boswellic acid analogue(s) in mono and combination therapy (with 5-FU) targeting KRAS in colorectal cancer. Arem Qayum, CSIR-IIIM, Jammu, Jammu/Kashmir, India.
B33; PR11 KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer. Y. Alan Wang, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

B34 eIF2B5 limits global protein synthesis to prevent MYC-dependent apoptosis in APC-deficient colorectal cancer. Armin Wiegering, Theodor Boveri Institute, Biocenter, University of Würzburg, Am Hubland, Würzburg, Germany.

B35 Amyloid precursor protein promotes tumor stemness and is a potential target in colorectal cancer. Hanwen Xu, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

B36; PR08 Trajectory space analysis: Leveraging computational models and single cell RNAseq to understand genetic programs defining intestinal lineages and infer colon stem cells in mouse. Denis Dermadi Bebek, Stanford University, Palo Alto, CA, USA.

B37 A Chemosensitivity Study of Colorectal Cancer Using Xenografts of Patient-Derived Tumor Initiating Cells. M. Mark Taketo, Kyoto University Graduate School of Medicine, Kyoto, Japan.


B39 A novel patient derived orthotopic xenograft model of gastro-esophageal junction cancer: key platform for translational discoveries. Omkara Lakshmi Veeranki, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.